Want to join the conversation?
$CELG said its cancer drug received approval to treat patients with newly diagnosed multiple myeloma in Japan. The approval was based on safety and efficacy results from an international phase 3 study, the FIRST trial as the pivotal study, as well as a confirmatory Japanese phase 2 study. This expands upon approval of REVLIMID in 2010.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.